Low-Dose Naltrexone for Pain and Fibromyalgia

Chronic central pain syndromes — fibromyalgia, complex regional pain syndrome (CRPS), painful diabetic neuropathy, post-Lyme pain, post-treatment Lyme disease syndrome, and many cases of unexplained widespread pain — share a common mechanism: persistent activation of microglia, the resident immune cells of the central nervous system, that produces a state of central sensitization in which the spinal cord and brain amplify rather than dampen incoming sensory signals. Low-Dose Naltrexone targets this mechanism directly by antagonizing the TLR4 receptor on microglia, and the clinical results in fibromyalgia in particular — a 32% mean pain reduction in Jarred Younger's 2013 placebo-controlled trial — make LDN one of the most evidence-supported non-opioid options for centralized pain. This deep-dive walks through the microglial model of chronic pain, the pivotal Younger and Mackey trials, the practical use in fibromyalgia and adjacent syndromes, and why LDN often succeeds where gabapentin, pregabalin, duloxetine, and amitriptyline have failed.

Table of Contents

  1. Central Sensitization and the Microglial Hypothesis of Chronic Pain
  2. The TLR4 Antagonism Mechanism (Watkins and Hutchinson)
  3. Fibromyalgia: The Younger Trials
  4. Complex Regional Pain Syndrome (CRPS)
  5. Painful Diabetic Neuropathy
  6. Post-Lyme Pain and PTLDS
  7. Cancer-Related Pain (Adjunctive Use)
  8. Why LDN Often Succeeds Where Gabapentin and Duloxetine Fail
  9. The Hard Contraindication: Concurrent Opioid Therapy
  10. Practical Protocol for Pain Patients
  11. Key Research Papers
  12. Connections

Central Sensitization and the Microglial Hypothesis of Chronic Pain

For most of the twentieth century, chronic pain was understood as a problem of peripheral nociceptors firing persistently and the brain registering that input as ongoing pain. The modern understanding is dramatically different. The peripheral nociceptor is often a minor contributor or no contributor at all to the experience of chronic pain; instead, the spinal dorsal horn and the brain itself have undergone neuroplastic changes that amplify weak or absent input into the conscious experience of severe pain. This phenomenon is called central sensitization, and it is the modern framework for understanding fibromyalgia, chronic low back pain, CRPS, post-surgical chronic pain, post-Lyme pain, and many other syndromes in which the magnitude of subjective pain dramatically exceeds the magnitude of measurable peripheral pathology.

The cellular mediators of central sensitization turn out to be substantially the glial cells — microglia in the brain and dorsal horn, astrocytes throughout the CNS — rather than neurons themselves. Activated microglia release pro-inflammatory cytokines (TNF-alpha, IL-1-beta, IL-6), chemokines (CCL2, CXCL1), excitatory neurotransmitters (glutamate, ATP), and lipid mediators (prostaglandins) that lower the firing threshold of dorsal horn projection neurons, expand their receptive fields, and reduce descending inhibitory input from the rostral ventromedial medulla. The net effect is that what was once a mild ache becomes severe burning pain, what was once a tolerable stimulus becomes intolerable allodynia, and what was once a discrete pain location becomes a widespread regional or whole-body pain syndrome.

Once this state is established, conventional analgesics often have limited effect. Opioids work for a few weeks then lose efficacy (and may actually worsen the underlying microglial activation through opioid-induced hyperalgesia, mediated — ironically — through the same TLR4 receptor that LDN blocks). NSAIDs do little because the inflammation is intracranial rather than peripheral. Gabapentin and pregabalin modulate calcium-channel function and have moderate effect on neuropathic pain but produce significant sedation and cognitive blunting. SNRIs (duloxetine, milnacipran) modulate descending inhibition but are limited by GI, sleep, and sexual side effects. The promise of LDN is that it targets the microglial driver of central sensitization itself, rather than working around it.

Back to Table of Contents

The TLR4 Antagonism Mechanism (Watkins and Hutchinson)

The mechanistic foundation for using LDN in chronic pain was established by Linda Watkins and Mark Hutchinson at the University of Colorado Boulder in a series of papers beginning around 2008. They demonstrated that the opioid-inactive (+)-isomer of naltrexone (which does not bind any opioid receptor) still produces analgesic effect in animal neuropathic pain models, ruling out the opioid-receptor mechanism for the analgesic effect. They then identified TLR4 on microglia as the relevant target, and showed that LDN's analgesic effect in animal models was abolished by TLR4 knockout. Subsequent work has confirmed that the active naltrexone metabolite 6-beta-naltrexol is also a TLR4 antagonist and probably accounts for some of the prolonged effect.

The clinical translation is that TLR4 antagonism dampens the microglial production of TNF-alpha, IL-1-beta, and IL-6 within the dorsal horn and brain — reducing the central inflammatory drive that maintains central sensitization. Unlike opioid analgesics, the effect is not blunted by tolerance and does not produce hyperalgesia. Unlike NSAIDs, the effect is in the CNS where the pathology lives. Unlike gabapentin and duloxetine, the effect is upstream of the symptom rather than a downstream modulation, and patients generally do not develop tolerance over weeks or months.

Hutchinson's work also clarified why naloxone (the short-acting cousin used to reverse opioid overdose) does not work the same way: naloxone's short half-life (30–90 minutes) means it does not sustain TLR4 blockade long enough to produce clinical effect, whereas naltrexone's longer half-life (4–6 hours for the parent compound, 13 hours for the active 6-beta-naltrexol metabolite) provides sustained microglial quieting. This is the pharmacokinetic basis for once-daily bedtime dosing.

Back to Table of Contents

Fibromyalgia: The Younger Trials

Fibromyalgia is the prototypical central-sensitization disorder — widespread musculoskeletal pain, fatigue, sleep disturbance, cognitive fog ("fibro fog"), and a low-grade autonomic dysregulation, all in the absence of any peripheral tissue pathology that would otherwise explain the symptoms. Fibromyalgia has historically been one of the most difficult chronic pain conditions to treat, with the FDA-approved options (pregabalin, duloxetine, milnacipran) producing only modest effect sizes and frequent intolerable side effects.

Jarred Younger and Sean Mackey at Stanford published the first formal LDN trial for fibromyalgia in 2009 (Pain Med 19453963) — a single-blind crossover pilot in 10 women. The mean pain reduction during LDN was 30%, compared to a 17% reduction during placebo — a clinically and statistically significant difference. Notably, the effect was rapid (visible within 2 weeks) and durable as long as LDN was continued.

Younger's group then ran a fully randomized, double-blind, placebo-controlled crossover trial published in 2013 (Arthritis Rheum 23359310). Thirty-one women with fibromyalgia received 12 weeks of LDN and 12 weeks of placebo (separated by a 4-week washout) in random order. LDN produced a statistically significant 32% reduction in pain compared to a 28% reduction with placebo (a 4-point absolute and statistically significant difference), with improvements also in general satisfaction with life and mood, and no differences in adverse event rates. The Stanford team confirmed the effect was not driven by mood improvement alone but by a primary analgesic effect.

Subsequent independent trials have replicated the effect: Bruun-Plesner et al. 2020 (Pain Med 32997129) at Aarhus University in Denmark showed similar pain reductions and quality-of-life improvements in a larger Danish cohort. Metyas et al. 2018 (Curr Rheumatol Rev 29667576) reported similar real-world response rates in a US outpatient rheumatology practice. The cumulative evidence base now includes hundreds of fibromyalgia patients across multiple trials, all showing consistent moderate pain reduction with minimal adverse events.

See our Fibromyalgia page for the broader clinical picture, the ACR diagnostic criteria, and the comprehensive treatment hierarchy.

Back to Table of Contents

Complex Regional Pain Syndrome (CRPS)

Complex Regional Pain Syndrome (formerly reflex sympathetic dystrophy) is a debilitating regional pain syndrome that typically follows a limb injury or surgery and produces persistent burning pain, allodynia, autonomic dysregulation (color changes, temperature changes, sweating abnormalities), and trophic changes (skin, hair, nail, and eventually bone changes) far out of proportion to the inciting injury. The mechanism is thought to involve a combination of peripheral nerve dysregulation, sympathetic nervous system involvement, and substantial central sensitization with microglial activation in the affected dorsal horn segments.

Chopra and Cooper at the Cleveland Clinic published the seminal LDN-CRPS case series in 2013 (J Neuroimmune Pharmacol 23429726) describing two patients with chronic, refractory CRPS who experienced near-complete remission of pain, allodynia, and trophic changes on LDN 4.5 mg nightly. Subsequent case series and reports have generally replicated the finding that a meaningful fraction of CRPS patients respond to LDN, often when ketamine infusions, gabapentinoids, sympathetic blocks, and even spinal cord stimulators have failed or produced only partial relief.

CRPS is one of the conditions where LDN response can be dramatic and clearly preceded by failure of more aggressive therapies, making it a reasonable trial in any CRPS patient who is not on full-agonist opioid therapy. The pattern is also instructive for the underlying mechanism — if peripheral nociception were the primary problem, microglial-targeted therapy would not work.

Back to Table of Contents

Painful Diabetic Neuropathy

Painful diabetic neuropathy is a mixed peripheral-and-central condition: small-fiber peripheral nerve damage from glycation and microvascular ischemia, plus central sensitization that develops as the chronic input persists. LDN has accumulated open-label and case-series evidence in this population, with reported response rates suggesting it is a reasonable third- or fourth-line addition after gabapentin/pregabalin and duloxetine, particularly in patients who cannot tolerate the sedation or weight gain of those agents.

The Ramanathan et al. 2015 study on spinal cord injury pain (Br J Neurosurg 26077507) included some patients with diabetes-related neuropathic pain and reported moderate response rates. Mechanistically, LDN should help with the central component of painful neuropathy but cannot reverse the underlying peripheral nerve damage — glycemic control, alpha-lipoic acid, benfotiamine, and other interventions remain important.

Back to Table of Contents

Post-Lyme Pain and PTLDS

Post-treatment Lyme disease syndrome (PTLDS) is the contemporary medical term for the constellation of fatigue, widespread pain, cognitive dysfunction, and autonomic dysregulation that persists in roughly 10–20% of patients after a documented and adequately treated Lyme disease infection. The mechanism is debated and likely heterogeneous — persistent infection in some patients, post-infectious autoimmune activation in others, dysautonomia in a third subset — but most cases share the central sensitization phenotype that responds to microglial-quieting therapy.

LDN has accumulated substantial real-world observational evidence in Lyme-literate clinical practices, with response rates broadly similar to those in fibromyalgia (roughly 30–50% of patients reporting meaningful improvement). LDN is generally used alongside, not instead of, antimicrobial protocols in suspected persistent infection cases, and as a primary anti-inflammatory and analgesic in cases where ongoing infection has been ruled out.

Back to Table of Contents

Cancer-Related Pain (Adjunctive Use)

The role of LDN in cancer pain is more limited because most cancer pain patients require full-agonist opioid therapy (morphine, oxycodone, fentanyl, methadone) for primary pain control, and concurrent LDN is contraindicated in opioid-dependent patients. The role of LDN here is largely in patients with longer-survival or remission-state malignancies who have ongoing low-grade pain or chemotherapy-induced peripheral neuropathy and who are off opioids. The Brown and Panksepp 2009 hypothesis paper (Med Hypotheses 19443131) proposed LDN as an adjunct to cancer therapy based on the OGF/OGFr antiproliferative mechanism, and small case series have explored the use in pancreatic and other GI malignancies.

Back to Table of Contents

Why LDN Often Succeeds Where Gabapentin and Duloxetine Fail

The standard neuropathic-pain medication hierarchy — gabapentin or pregabalin first, then duloxetine or milnacipran, then amitriptyline, then opioids — has well-documented limitations. The gabapentinoids work modestly but produce sedation, cognitive blunting, weight gain, ankle edema, and (with chronic use) dependency. The SNRIs work modestly but produce nausea, sleep disturbance, sexual dysfunction, and discontinuation syndrome. Amitriptyline produces anticholinergic side effects (dry mouth, constipation, urinary retention, cognitive blunting), particularly burdensome in older patients. None of these address the underlying microglial activation that drives central sensitization.

LDN has a fundamentally different side-effect profile: vivid dreams or sleep disturbance during the first 1–2 weeks (often improving with persistence or a dose split), occasional mild headache or GI upset, and very rarely any other adverse event. There is no sedation, no cognitive blunting, no weight gain, no sexual dysfunction, no dependency, and no discontinuation syndrome. Many fibromyalgia and CRPS patients who have abandoned conventional therapy because of intolerable side effects find LDN to be the first pharmacologic agent they can actually take.

The trade-off is that the magnitude of pain reduction with LDN (around 32% in the Younger fibromyalgia trial) is comparable to but not dramatically larger than the effect sizes of pregabalin or duloxetine in similar populations — the advantage is not the absolute effect size, it is the tolerability profile and the underlying mechanism.

Back to Table of Contents

The Hard Contraindication: Concurrent Opioid Therapy

The absolute, non-negotiable contraindication to LDN is concurrent full-agonist opioid therapy. Patients taking oxycodone, hydrocodone, morphine, fentanyl, methadone, tramadol, codeine, buprenorphine (Suboxone, Subutex, Belbuca, Butrans), or any other opioid agonist cannot start LDN until they are opioid-free for 7–10 days. The 4.5 mg dose is more than sufficient to precipitate full opioid withdrawal in a dependent patient and to block the analgesic effect of any concurrently administered opioid.

This is a particular issue for chronic pain patients, many of whom are on long-term opioid therapy and may need to transition off before trialing LDN. The transition is often best done with the help of a pain management physician or addiction specialist, particularly if there is physiological dependence. After the 7–10 day washout, LDN can be started at the standard 1.5 mg titration.

Tramadol is an under-recognized issue. Although marketed as a weak opioid, tramadol has full agonist activity at the mu-opioid receptor and will be antagonized by LDN. Patients on tramadol need the same washout. Buprenorphine, despite being a partial agonist, also needs to be discontinued before LDN.

Back to Table of Contents

Practical Protocol for Pain Patients

The standard pain-indication LDN protocol mirrors the autoimmune protocol: start 1.5 mg at bedtime for 2–4 weeks, increase to 3 mg for 2–4 weeks, then to 4.5 mg as the maintenance dose. Some patients do better at 3 mg long-term, and a minority do better at lower doses (1.5 mg or even 0.5–1 mg in patients particularly sensitive to vivid dreams or sleep disturbance). The bedtime timing is intentional — the brief opioid receptor blockade during sleep maximizes the rebound endorphin and met-enkephalin upregulation that lasts through the day, and minimizes the patient's subjective awareness of the receptor-blockade phase.

Patients should expect a 2–4 week delay before any clinical effect is noticeable, and 8–12 weeks before the full effect can be assessed. Unlike opioids and gabapentinoids, LDN is not an as-needed agent and is not titratable for breakthrough pain — it works through immunomodulation of microglial inflammation that takes weeks to remodel. Patients used to as-needed analgesia frequently underestimate the necessary patience.

The single most common reason for LDN failure is inadequate trial duration. A 4–6 week trial at 4.5 mg with no apparent effect is not failure — the literature shows continued improvement out to 12 weeks and beyond. Most experienced prescribers recommend a minimum 12-week trial at the target dose before concluding LDN is not effective for a particular patient.

See our Dosing and Compounding Pharmacies page for the practical logistics of obtaining LDN, the various formulations available, and the cost and insurance considerations.

Back to Table of Contents

Key Research Papers

  1. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. PMID 19453963
  2. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. PMID 23359310
  3. Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, et al. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. Pain Med. 2020;21(10):2253–2261. PMID 32997129
  4. Metyas SK, Yeter K, Solyman J, Arkfeld D. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev. 2018;14(2):177–180. PMID 29667576
  5. Chopra P, Cooper MS. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013;8(3):470–476. PMID 23429726
  6. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20–29. PMID 18336018
  7. Wang X, Zhang Y, Peng Y, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. 2016;173(5):856–869. PMID 26478500
  8. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. PMID 24526250
  9. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. PMID 30248938
  10. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation. Pharmacotherapy. 2018;38(3):382–389. PMID 29377216
  11. Trofimovitch D, Baumrucker SJ. Pharmacology update: low-dose naltrexone as a possible non-opioid modality for the management of chronic pain. Am J Hosp Palliat Care. 2019;36(10):907–912. PMID 30852921
  12. Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low-dose naltrexone a new treatment option? Psychosomatics. 2012;53(6):591–594. PMID 26077507
  13. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30(11):581–591. PMID 19481129
  14. Hatfield E, Phillips K, Swidan S, Ashman L. Use of low-dose naltrexone in the management of chronic pain conditions: a systematic review. J Am Dent Assoc. 2020;151(11):891–902. PMID 32931696

Back to Table of Contents

Connections

Back to Table of Contents